Skip to content
2000
Volume 13, Issue 8
  • ISSN: 1381-6128
  • E-ISSN: 1873-4286

Abstract

Unlike the more commonly used diuretics, aquaretic agents can induce an increase in urinary volume without incurring a loss of electrolytes. These molecules belong to a family of vasopressin receptor antagonists, V2 in particular, that regulate optional renal water re-absorption via the synthesis and expression of aquaporin-2. In view of their properties, they have become the agent of choice in the treatment of hyponatremic states with water retention, and different studies have demonstrated that they are more effective and practical to use than other traditional approaches in the treatment of diseases such as cirrhosis-related ascites, SIADH and, above all, heart failure. However, the future probably holds the promise of new and unexpected applications for this type of drug in the treatment of several conditions, including polycystic kidney and glomerular disease, glaucoma and Meniere's syndrome.

Loading

Article metrics loading...

/content/journals/cpd/10.2174/138161207780363040
2007-03-01
2025-04-15
Loading full text...

Full text loading...

/content/journals/cpd/10.2174/138161207780363040
Loading

  • Article Type:
    Research Article
Keyword(s): Aquaretic; heart failure; hyponatremia; V2 antagonists; vasopressin
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test